Eric A Meyerowitz
Overview
Explore the profile of Eric A Meyerowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shaffer A, Meyerowitz E
Infect Dis Clin North Am
. 2025 Mar;
PMID: 40068975
While most SARS-CoV-2 infections and reinfections in the era of widespread population immunity with omicron subsub-lineage variants are mild for immunocompetent individuals, any manifestation previously seen during the pandemic phase...
2.
Mullis C, Bishop D, Fazzari M, Tappen N, Felsen U, Meyerowitz E
Clin Infect Dis
. 2025 Mar;
PMID: 40066683
Doxy-PEP is used to prevent chlamydia, syphilis and gonorrhea infections in sexual and gender minority men and transgender women. We describe a systematic process for developing algorithms that allow for...
3.
Meyerowitz E, Kim A
Open Forum Infect Dis
. 2024 Dec;
11(12):ofae697.
PMID: 39669775
No abstract available.
4.
Meyerowitz E, Liang R, Bishop D, Mullis C
PLoS Pathog
. 2024 Sep;
20(9):e1012575.
PMID: 39348354
No abstract available.
5.
Coe J, Puius Y, Jain H, Meyerowitz E
BMJ Case Rep
. 2024 Mar;
17(3).
PMID: 38490710
We present an instructive case of cervical lymphadenitis in a young man without a history of HIV infection. The patient developed spontaneous left-sided neck swelling that progressed over 4 months....
6.
Meyerowitz E, Roy S, Neilan A, Ross D, Mahowald G
N Engl J Med
. 2024 Feb;
390(7):653-660.
PMID: 38354145
No abstract available.
7.
Meyerowitz E, Scott J, Richterman A, Male V, Cevik M
Nat Rev Microbiol
. 2023 Dec;
22(2):75-88.
PMID: 38114838
The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in humans. The current high levels of population immunity, due to prior infection and/or vaccination, have been associated with...
8.
Mullis C, Marlow K, Maity A, Fazzari M, Zingman B, Keller M, et al.
Sex Transm Dis
. 2023 Dec;
51(3):199-205.
PMID: 38100794
Background: Mycoplasma genitalium (MG) is an emerging sexually transmitted infection. Treatment of MG is complicated by increasing resistance to primary treatment regimens, including macrolides and fluoroquinolones. Understanding the various clinical...
9.
Irshad U, Bishop D, Mullis C, Toro J, Zingman B, Meyerowitz E
Open Forum Infect Dis
. 2023 Nov;
10(11):ofad544.
PMID: 38023548
Mpox caused a global outbreak in 2022. Among 249 people who received mpox vaccination at a sexual health clinic in the Bronx, New York, those with private vs public insurance...
10.
Meyerowitz E, Li Y
Clin Infect Dis
. 2023 Nov;
78(4):908-917.
PMID: 37949817
The goals of coronavirus disease 2019 (COVID-19) antiviral therapy early in the pandemic were to prevent severe disease, hospitalization, and death. As these outcomes have become infrequent in the age...